Pulsed-field ablation, transcatheter heart valves, and IVL are among the top stories, as they drive growth among the largest ...

Boston Scientific shares trade at $91.87, down 16% from their 52-week high of $109.50, but analysts remain bullish. Thirty-three of 34 analysts rate the stock a buy, with a mean price target of ...

The Zacks Medical - Products industry is grappling with a challenging operating environment due to the tariffs imposed by the United States on multiple trading partners, including China, Europe and ...

Medtronic (NYSE:MDT) reported new positive post-market clinical evidence for its Penditure left atrial appendage (LAA) ...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational 1 basis and ...

McLaren Northern Michigan performed 75 transcatheter aortic valve replacement procedures in 2025, more than double the previous year. Cardiologist Dr. Siddharth Gandhi performed the procedures, up ...

In a first, this week the U.S. Food and Drug Administration approved a brain stimulation device designed to treat depression at home. The approval of the first such device for home depression ...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025 ...

Good morning, and thank you for standing by. Welcome to Abbott's Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded by Abbott. With the exception of any ...

Earnings call Abbott reported Q4 adjusted EPS of $1.50, up 12% YoY, and organic sales growth of 3.8% excluding COVID testing. For 2026, the company guided to 6.5%-7.5% organic sales growth and 10% EPS ...